Compare · ANPC vs ILMN
ANPC vs ILMN
Side-by-side comparison of AnPac Bio-Medical Science Co. Ltd. (ANPC) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANPC and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $51.89B, about 1374.5x ANPC ($37.7M).
- ILMN has hit the wire 5 times in the past 4 weeks while ANPC has been quiet.
- ILMN has more recent analyst coverage (25 ratings vs 0 for ANPC).
- Company
- AnPac Bio-Medical Science Co. Ltd.
- Illumina Inc.
- Price
- $4.53-7.74%
- $127.93+2.01%
- Market cap
- $37.7M
- $51.89B
- 1M return
- -
- +1.37%
- 1Y return
- -
- +65.69%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2000
- News (4w)
- 0
- 5
- Recent ratings
- 0
- 25
AnPac Bio-Medical Science Co. Ltd.
AnPac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests to corporations and life insurance companies in the People's Republic of China. It offers cancer differentiation analysis devices and physical checkup package services. The company was incorporated in 2010 and is headquartered in Lishui, the People's Republic of China.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest ANPC
- AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits
- AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 3 filed by new insider Liang Zhijun
- SEC Form 3 filed by new insider Zhao Zhigang
- SEC Form 3 filed by new insider Li Xiaoyu
- SEC Form 3 filed by new insider Pu Tianruo
- SEC Form 3 filed by new insider Tian Honggang
- New insider Xu Haohan claimed ownership of 69,774,679 units of Class A Ordinary Shares (SEC Form 3) (Amendment)
Latest ILMN
- DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows
- Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease
- Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026
- SEC Form DEFA14A filed by Illumina Inc.
- SEC Form DEF 14A filed by Illumina Inc.
- SEC Form 4 filed by Ullem Scott B.
- SEC Form 4 filed by Meister Keith A.
- Illumina Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Illumina Announces Changes to Board of Directors
- Amendment: SEC Form SCHEDULE 13G/A filed by Illumina Inc.